Molecular Mechanisms of Combination Adjuvants (MMCA) (U01 Clinical Trial Not Allowed) | RFA AI 20 004

Opportunity Information: Apply for RFA AI 20 004

The Molecular Mechanisms of Combination Adjuvants (MMCA) funding opportunity (RFA AI 20 004) is a National Institutes of Health, NIAID-sponsored cooperative agreement (U01; clinical trial not allowed) focused on advancing the basic and translational science of vaccine adjuvants used in combination. The central purpose is to support research that explains, at a molecular and cellular level, how two or more adjuvants work together to enhance immune responses beyond what each adjuvant can achieve alone. A key requirement is that the adjuvants proposed for combination studies must already have demonstrated individual immune-modulating activity, so the work builds on established signals and aims to dissect how synergy (or other interaction patterns) arises when adjuvants are paired or grouped.

The scientific emphasis is on mechanism of action. Projects are expected to move past descriptive immunogenicity readouts and instead clarify the pathways and cell types driving improved responses, such as how innate sensing triggers shape antigen presentation, germinal center dynamics, T cell polarization, B cell maturation, and the quality and durability of antibody and cellular immunity. By mapping these mechanisms, NIAID aims to make adjuvant selection more rational and pathogen-specific, meaning investigators should be working toward principles that help match particular adjuvant combinations to the needs of different vaccine targets (for example, pathogens requiring strong neutralizing antibodies versus those requiring potent CD8 T cell responses or mucosal immunity).

Because this is a U01 cooperative agreement, it is designed for coordinated research with significant programmatic involvement from NIAID compared with a standard investigator-initiated grant. In practice, that typically means funded teams should expect active collaboration and alignment with NIAID’s broader adjuvant research objectives, shared priorities around experimental approaches or data types, and coordination across awards where appropriate. The longer-term public health goal is to accelerate the development of novel adjuvant combinations that improve vaccine immunogenicity while limiting or eliminating reactogenicity, reflecting an interest not only in stronger immune responses but also in understanding and reducing the biological drivers of adverse inflammatory effects.

The opportunity sits within the NIH health research mission (CFDA 93.855) and supports discretionary funding via a cooperative agreement mechanism. The award ceiling listed is $400,000, and the original closing date for the opportunity was 2020-07-20 (created 2020-02-06). While the posting does not specify the expected number of awards in the provided text, it frames the program as a coordinated effort rather than a single-project initiative, implying multiple complementary awards could be supported depending on availability of funds and meritorious applications.

Eligibility is broad and explicitly inclusive of a wide range of organizations. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofits with or without 501(c)(3) status (outside higher education); for-profit organizations (other than small businesses) as well as small businesses; public housing authorities/Indian housing authorities; and Native American tribal governments (federally recognized) and other Native American tribal organizations. The FOA also highlights additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations), indicating an intent to attract diverse institutional perspectives and capabilities, including international expertise where it strengthens mechanistic adjuvant science.

Overall, MMCA is aimed at filling a specific gap in vaccine development: understanding why and how adjuvant combinations can be more effective than single agents, and using that knowledge to guide safer, more potent, and more precisely tailored vaccine formulations. By funding mechanistic studies under a cooperative framework, NIAID is effectively trying to turn combination adjuvant design from trial-and-error into a more predictive, pathway-informed process that can be applied across multiple pathogens and vaccine platforms.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Molecular Mechanisms of Combination Adjuvants (MMCA) (U01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
• This funding opportunity was created on 2020-02-06.
• Applicants must submit their applications by 2020-07-20. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $400,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA AI 20 004

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: